SOL-GEL TECHNOLOGIES LTD (SLGL) Stock Price & Overview
NASDAQ:SLGL • IL0011417206
Current stock price
The current stock price of SLGL is 79.46 USD. Today SLGL is down by -4.84%. In the past month the price increased by 0.58%. In the past year, price increased by 1606.62%.
SLGL Key Statistics
- Market Cap
- 221.693M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -10.10
- Dividend Yield
- N/A
SLGL Stock Performance
SLGL Stock Chart
SLGL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SLGL. When comparing the yearly performance of all stocks, SLGL is one of the better performing stocks in the market, outperforming 99.76% of all stocks.
SLGL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SLGL. No worries on liquidiy or solvency for SLGL as it has an excellent financial health rating, but there are worries on the profitability.
SLGL Earnings
SLGL Forecast & Estimates
7 analysts have analysed SLGL and the average price target is 112.2 USD. This implies a price increase of 41.2% is expected in the next year compared to the current price of 79.46.
For the next year, analysts expect an EPS growth of 97.17% and a revenue growth 870.39% for SLGL
SLGL Groups
Sector & Classification
SLGL Financial Highlights
Over the last trailing twelve months SLGL reported a non-GAAP Earnings per Share(EPS) of -10.1. The EPS decreased by -54.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.48% | ||
| ROE | -26.86% | ||
| Debt/Equity | 0 |
SLGL Ownership
SLGL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.764B | ||
| PFE | PFIZER INC | 9.48 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 125.711B | ||
| ZTS | ZOETIS INC | 16.66 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 27.972B | ||
| VTRS | VIATRIS INC | 5.36 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLGL
Company Profile
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Company Info
IPO: 2018-02-01
SOL-GEL TECHNOLOGIES LTD
Golda Meir 7
Ness Ziona 7403648 IL
CEO: Alon Seri-Levy
Employees: 34
Phone: 97289313433
SOL-GEL TECHNOLOGIES LTD / SLGL FAQ
Can you describe the business of SOL-GEL TECHNOLOGIES LTD?
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Can you provide the latest stock price for SOL-GEL TECHNOLOGIES LTD?
The current stock price of SLGL is 79.46 USD. The price decreased by -4.84% in the last trading session.
Does SLGL stock pay dividends?
SLGL does not pay a dividend.
What is the ChartMill technical and fundamental rating of SLGL stock?
SLGL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How many employees does SOL-GEL TECHNOLOGIES LTD have?
SOL-GEL TECHNOLOGIES LTD (SLGL) currently has 34 employees.
What is the ownership structure of SOL-GEL TECHNOLOGIES LTD (SLGL)?
You can find the ownership structure of SOL-GEL TECHNOLOGIES LTD (SLGL) on the Ownership tab.
Can you provide the short interest for SLGL stock?
The outstanding short interest for SOL-GEL TECHNOLOGIES LTD (SLGL) is 2.19% of its float.